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behavioural and physiologic pain assessment methods were tested
on OA dogs, and compared to peak vertical force (PVF) measured
on gait analysis. Our hypothesis was that these instruments would
correlate to PVF.
Methods: Twenty-three dogs with lameness were enrolled in the
study. Lameness was conﬁrmed with PVF gait analysis, radio-
graphical and clinical orthopaedic diagnosis. Prior to the ﬁrst eval-
uation, wash out periods were respected for OA pharmaceutical
treatments, nutraceuticals, fatty acid supplement and therapeutic
diets or threats. The clinical trial began with a 30-day period during
which all dogs received a ﬁrst diet. After this period, dogs received
a second diet for a subsequent 60-days period. Owners evaluated
pain using two behavioural rating scales: a standardized multifac-
torial questionnaire (MFQ) and a case-speciﬁc functional assess-
ment (CODI) performed twice per week. Owners scored MFQ at
D0, D30 and D90 with the assistance of a veterinarian. Clinical ex-
amination included measurement of electrodermal activity (EDA),
body weight, and PVF at D0, D30 and D90. A pilot evaluation of
locomotor activity including three parameters [“daily averaged total
intensity” (DATI), “daily peak intensity” (DPI) and “daily proportion
of active period” (DPAP)] was recorded every 2 minutes over the
90-day, using telemetric accelerometer (Actical®/Actiwatch®) on
six dogs. Data analysis and statistics: PVF was corrected to body
weight changes. MFQ and CODI were transformed to be ranged
from 0 (higher pain) to 100 (lower pain).Outcomes of locomotor
activity were averaged for every week of data acquisition. ANOVA
for repeated measures followed by Tukey-Kramer multiple compar-
isons test were applied. Friedman test was used when justiﬁed.
Spearman’s rank correlation coefﬁcient was fulﬁlled to evaluate
construct validation.
Results: MFQ and CODI increased from D0 to D90 (p<0.05).
EDA showed high variability and was unchanged over time. Body
weight was changed over time, and PVF adjusted to body weight
values were at D0: 65.7 (21.0), D30: 67.3 (19.7), and D90: 69.9
(21.3) (p=0.03). For locomotor activity, DATI and DPI were stable
from D0 to D30 but increased from D0 to D90 (p<0.05).
CODI and MFQ were positively correlated (rho = 0.45, p<0.001).
CODI was positively correlated to the DATI of locomotor activity
over the 12 weeks of recording (rho = 0.42, p<0.001). PFV
adjusted to body weight trended to correlate to DATI from D0 to
D30 (p=0.11), and descriptive analysis demonstrated at D90 that
PVF increase was also associated to increase in DATI, DPI and
DPAP.
Conclusions: CODI, the behavioural pain rating scale developed
for each speciﬁc dog and owner, was indicator of level of activity
in dogs, but was not correlated to orthopaedic disability per se.
Gait analysis was indicator of orthopaedic ability and endurance
to be active. CODI and gait analysis had good construct validation
and were complementary evaluations to evaluate chronic pain
caused by OA in dogs. Locomotor activity looks as an objective
behavioural evaluation and a potent complement to PVF gait
analysis.
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Purpose: Glucosamine sulphate (GS) and chondroitin sulphate
(CS) are symptomatic slow-acting drugs for osteoarthritis (OA)
widely used in clinic. However, their mechanism of action re-
mains poorly characterized. Since the variability in the treatment
efﬁcacy of these compounds is in accordance with the patholog-
ical OA degree (severe-moderate-mild), we decided to carry out
our experiments in normal chondrocyte cultures stimulated with
Interleukin-β. IL-1β is an arthritic mediator with the capacity to
drive the key pathways typically associated with the pathogen-
esis of OA. The aim of this work is to explore the utility of a
pharmacoproteomic approach for the identiﬁcation of mechanisms
and speciﬁc molecules involved in the pharmacological effect of
glucosamine sulphate and chondroitin sulphate.
Methods: Chondrocytes obtained from 3 healthy donors were
treated with GS 10mM and/or CS 200μg/mL, and then stimulated
with IL-1β 10ng/mL. Whole cell proteins were isolated 24 hours
after cellular stimulation and resolved by two-dimensional elec-
trophoresis. The gels were stained with SYPRORuby and digitized
using a CCD camera. The image analysis was performed using the
PDQuest 7.3.1 computer software. Differentially abundant proteins
were identiﬁed by matrix-assisted laser desorption/ionization-time
of ﬂight mass spectrometry. Visualization of modulated biological
pathways was carried out using Pathway Studio software. Real-
time and western blot analyses were performed to validate our
results.
Results: We examined a mean of 500 protein spots that were
present in each gel. Both qualitative and quantitative changes in
protein expression patterns between controls and treated cells
were studied. We identiﬁed 39 protein spots that were modulated
by GS treatment, 35 by CS treatment and 48 by GS+CS treatment
compared to the control. Database search showed that most of
these proteins are involved in protein folding (PDIA1, PDIA3),
stress response (HSP7C, HSPB1, ANXA2), cellular metabolism
(AK1C2, PGK1, KPYM), protein targeting (GRP78) and oxidative
stress (SOD2, PRDX1). Considering that oxidative stress balance
has been reported to play an essential role in osteoarthritis,
we found SOD2 upregulated by IL-1β and downregulated by
GS and CS treatment, both at transcription and protein levels.
Biological signiﬁcance of these data included the drug-dependent
decrease of superoxide dismutase activity that we detected in
cartilage cells, and also the reduction in ROS generation. On
the other hand, GRP78, a protein previously characterized by its
anti-inﬂammatory properties and recently proposed as a potential
new biologic therapy for RA, resulted increased by GS, alone and
in combined administration. This is the ﬁrst study carried out in
chondrocytes that conﬁrms the GS effect as positive modulator of
Grp78 expression and points to a speciﬁc mechanism of action of
this compound for its putative anti-inﬂammatory effect.
Conclusions: The present study uses an in vitro model of in-
ﬂammation (using IL-1β) to describe the effect of GS and CS on
cartilage cells. We have identiﬁed several novel molecular targets
of these compounds, such as SOD2 and GRP78, which may
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explain their reported good efﬁcacy in OA treatment. Our results
highlight the synergic effect of the combined administration and
point out the effectiveness of both molecules as anti-inﬂammatory
drugs.
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Purpose: The self-assembling peptide (KLDL)3, or KLD, has been
shown to have chondrogenic properties in vitro. In addition, TGF-
β1 and dexamethasone are crucial for inducing chondrogenesis
of bone marrow-derived stromal cells (BMSCs) in vitro, and IGF-1
promotes biosynthesis of sGAGs by chondrocytes. The goal of
this study was to optimize conditions to provide the best repair in
a rabbit model.
Methods: In Vitro Tissue Engineering: Bone marrow was har-
vested from bovine calves. BMSCs were selected via differential
adhesion and expanded 2 passages in LGDMEM with 10% FBS
& 5ng/mL FGF-2. KLD peptide (0.35% w/v) was pre-mixed with
100ng/mL TGF-β1 and 100nM dexamethasone, with or without
300 ng/mL IGF-1, prior to adding cells. BMSCs were encapsu-
lated in KLD/GF mixture at 10 million/mL. Gels were cultured in 1%
ITS + HGDMEM. sGAG retained in each hydrogel was quantiﬁed
by DMMB dye binding. DNA was quantiﬁed by Hoechst dye assay.
During the ﬁnal 24 h of culture, 5μ Ci/mL 35S-sulfate and 10μ
Ci/mL 3H-proline was added to medium to quantify proteoglycan
(PG) and protein synthesis.
In Vivo Rabbit Model: Three different conditions were tested: KLD
alone, KLD + GF, and KLD + GF + BMSCs. Based on the in vitro
study, 100ng/mL TGF-β1, 100 nM dexamethasone, and 300 ng/mL
IGF-1 were used together as the growth factor (GF) combination
pre-mixed with KLD prior to injection. BMSCs were allogenic. In 32
female 8-month-old New Zealand White rabbits, a 3mm diameter
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Figure 2. Representative Safranin-O staining for in vivo defect repair. KLD only
treated had signiﬁcantly higher staining than the bilateral empty control.
full-thickness defect was created in the femoropatellar groove of
each knee. GF and cells were pre-mixed with KLD and directly
injected into left-knee defects with right-knee defects left empty as
controls. There were 6-7 rabbits used for each condition. ACUC
approval was given by CSU. Repair tissue was analyzed by gross
and histological scoring.
Results: In vitro testing conﬁrmed that including IGF-1, along with
TGF-β1 and dexamethasone, improved chondrogenesis of BM-
SCs in KLD as shown by higher sGAG content and PG synthesis
(Fig. 1). However, in the rabbit model, the KLD group without any
growth factors or cells showed the greatest repair after 12 weeks.
KLD had a signiﬁcantly higher total histology score and more
Safranin-O staining (Fig. 2, 3). Including BMSCs with GF resulted
